Loading live market data…

Standard BioTools Inc.

NASDAQ:LAB

$0.8379 USD

-$0.01 (-1.28%)

Volume
2.61M
Average Volume
3.96M
Market Capitalization
$328.01M
P/E Ratio
-3.34
Dividend Yield
0.00%
Price Target
$3.25
Year High
$1.72
Year Low
$0.70
Day High
Day Low
Payout Ratio
$0.00
Current Ratio
$12.36
Source Headline
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AstroNova, Inc. (Nasdaq – ALOT), Open Lending Corporation (Nasdaq – LPRO), Huntsman Corporation (NYSE – HUN), Standard BioTools Inc. (Nasdaq – LAB)

BALA CYNWYD, Pa. , June 19, 2026 (GLOBE NEWSWIRE) -- Brodsky and Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith. com) or Marc Ackerman (mackerman@brodskysmith. com) at 855-576-4847.

globenewswire.com - 2026-06-19 12:48:57

LiveRamp Launches Agentic Partner Program to Fast-Track Agentic Deployments for Customers

SAN FRANCISCO--(BUSINESS WIRE)--LiveRamp (NYSE: RAMP), the leader in data collaboration, today announced LiveRamp Agent Builders (LAB), a new program to bring more partner-built agents into its network and accelerate marketers' ability to transform planning, measurement, activation, and data transformation with AI. During LAB's pilot period, brands will have access to agents from all of the AI companies participating in the program, enabling customers to focus on finding tools that create value.

businesswire.com - 2026-06-17 08:30:00

Are ROKU, PAYO, LAB, FOX Obtaining Fair Deals for their Shareholders?

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws

prnewswire.com - 2026-06-15 13:29:00

LAB Stock Alert: Halper Sadeh LLC is Investigating Whether Standard BioTools Inc. is Obtaining a Fair Price for its Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Standard BioTools Inc. (NASDAQ: LAB) and Treeline Biosciences, Inc. Upon closing

gurufocus.com - 2026-06-15 11:00:00

LAB Stock Alert: Halper Sadeh LLC is Investigating Whether Standard BioTools Inc. is Obtaining a Fair Price for its Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Standard BioTools Inc. (NASDAQ: LAB) and Treeline Biosciences, Inc. Upon closing of the proposed transaction, Standard BioTools shareholders are expected to own approximately 16% of the combined company. Halper Sadeh encourages Standard BioTools shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 o.

businesswire.com - 2026-06-15 10:11:00

Labrador Gold to Host Investor Webinar on the Mariposa Gold Project in Yukon's White Gold District

TORONTO, June 11, 2026 (GLOBE NEWSWIRE) -- Labrador Gold Corp. (TSX Venture: LAB) ("Labrador Gold" or the "Company") is pleased to announce that it will host a live investor webinar on Wednesday, June 17, 2026, at 12:00 PM PT / 3:00 PM ET, featuring President and CEO Roger Moss and moderated by Cory Fleck of the KE Report. The webinar will provide investors with an in-depth overview of the Company's recently acquired Mariposa Gold Project, including its strategic location within the Yukon's prolific White Gold District, historical exploration results, the recently approved Class 1 permit, planned 2026 exploration activities and upcoming catalysts as the Company advances this district-scale gold opportunity.

globenewswire.com - 2026-06-11 07:00:00

Labrador Gold Announces 2026 Exploration Plans for Pacific Ridge's White Gold Projects

Vancouver, British Columbia--(Newsfile Corp. - June 11, 2026) - Pacific Ridge Exploration Ltd. (TSXV: PEX) (OTCQB: PEXZF) (FSE: PQW) ("Pacific Ridge" or the "Company") is pleased to report that Labrador Gold Corp. (TSXV: LAB) ("LabGold") has announced plans for its 2026 exploration programs for the Company's Mariposa and Eureka Dome gold projects in the White Gold District, Yukon.

newsfilecorp.com - 2026-06-11 07:00:00

Standard BioTools Inc. (LAB) Discusses Merger and Strategic Rationale Prepared Remarks Transcript

Standard BioTools Inc. (LAB) Discusses Merger and Strategic Rationale Prepared Remarks Transcript

seekingalpha.com - 2026-06-08 22:28:46

Standard BioTools and Treeline Biosciences Announce Merger Agreement

Combined company to operate as Treeline Biosciences, advancing a deep pipeline of small molecule inhibitors, protein degraders and targeted therapy antibody-drug conjugates

globenewswire.com - 2026-06-08 07:30:00

Standard BioTools (LAB) Reports Q1 Loss, Tops Revenue Estimates

Standard BioTools (LAB) came out with a quarterly loss of $0.02 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.04 per share a year ago.

zacks.com - 2026-05-05 21:31:16

Standard BioTools Reports First Quarter 2026 Financial Results

BOSTON, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the quarter ended March 31, 2026.

globenewswire.com - 2026-05-05 16:05:00

Reviewing Standard BioTools (NASDAQ:LAB) & Zhongchao (NASDAQ:ZCMD)

Standard BioTools (NASDAQ: LAB - Get Free Report) and Zhongchao (NASDAQ: ZCMD - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership and profitability. Insider and Institutional Ownership 53.7% of Standard BioTools

defenseworld.net - 2026-04-27 02:38:50

Standard BioTools to Announce First Quarter 2026 Financial Results on May 5, 2026

BOSTON, Mass. , April 21, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will publish its first quarter 2026 financial results on Tuesday, May 5, 2026, after U. S. market close.

globenewswire.com - 2026-04-21 07:00:00

Get LAB Insider Trade Alerts

LAB Price Target Summary

Last Month

$0.00

0 analysts

Last Quarter

$0.00

0 analysts

Last Year

$0.00

0 analysts

All Time

$3.25

1 analysts

LAB Recent Analyst Grades

Date Analyst Firm Action Previous Grade New Grade
2025-11-05 TD Cowen Maintain Hold Hold
2025-02-27 Keybanc Downgrade Overweight Sector Weight
2024-10-31 TD Cowen Maintain Buy Buy
2024-08-01 TD Cowen Maintain Buy Buy
2020-08-26 UBS Maintain Buy Buy
2020-08-09 UBS Maintain Buy Buy
2019-11-05 Janney Montgomery Scott Downgrade Buy Neutral
2019-10-17 UBS Upgrade Neutral Buy
2019-01-02 Janney Montgomery Scott Upgrade Neutral Buy
2018-11-01 Piper Sandler Upgrade Neutral Overweight
2016-02-04 Mizuho Upgrade Neutral Buy
2016-02-04 Deutsche Bank Maintain Buy Buy
2016-01-19 Cowen & Co. Downgrade Outperform Market Perform
2015-11-01 Cantor Fitzgerald Upgrade Hold Buy
2015-10-29 Cantor Fitzgerald Upgrade Hold Buy
2015-10-01 Cowen & Co. Maintain Outperform Outperform
2015-08-06 Piper Sandler Downgrade Overweight Neutral
2015-05-07 Leerink Swann Maintain Outperform Outperform
2015-05-07 Mizuho Downgrade Buy Neutral
2015-03-04 Leerink Swann Maintain Outperform Outperform
2015-01-19 Cowen & Co. Upgrade Market Perform Outperform
2014-05-05 Piper Sandler Maintain Overweight Overweight
2014-04-13 Leerink Swann Upgrade Market Perform Outperform
2014-02-06 Cowen & Co. Downgrade Outperform Market Perform
2013-04-28 Leerink Swann Downgrade Outperform Market Perform
2012-10-08 Mizuho Downgrade Buy Neutral